A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette- Guerin

Journal of Urology

Volumn 156, Issue 3, 1996, Pages 962-966

  Krege, S ^o   Giani, G ^o   Meyer, R ^o   Otto, T ^o   Rubben H ^o   Noll, F ^a   Jakse, G ^b   Muller St ^c   Melchior, H J ^d   Weissbach, L ^e   Terhorst, B ^f   Lenz, P ^g   Faul, P ^h   Sommerkamp, H ⁱ   Kopper, B ^j   Hautmann, R ^k   Knebel, L ^l   Keller, ^m   Eisenberger, F ⁿ   Schaffner, W ^o  

^a Krankenhaus Bardenberg

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d KLINIKUM KASSEL   (Germany)

^e Institute of Pathology   (Germany)

^f Caritaskrankenhaus Bad Mergentheim   (Germany)

^g Krankenhaus Bad Soden   (Germany)

^h Krankenhaus Memmingen   (Germany)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j Städt Krankhs Kaiserslautern   (Germany)

^k UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

^l Elisabeth Krankenhaus   (Germany)

^m Kreiskrankenhaus Nagold   (Germany)

ⁿ KATHARINENHOSPITAL   (Germany)

^o NONE

more..

Author keywords

bladder neoplasms; chemotherapy; immunotherapy; mitomycin C

Indexed keywords

BCG VACCINE; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; CYSTITIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EPIDIDYMITIS; FEMALE; FEVER; HEMATURIA; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

EID: 9444281414     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65673-8     Document Type: Article

References (24)

1. Rübben, H. and Jocham, D.: Therapie des oberflächlichen Harnblasenkarzinoms. Urologe A, 30: 2, 1991.
2. Otto, T. and Rübben, H.: Management of T1 G3 bladder tumors. Eur. Urol. Update Series, 3: 122, 1994.
3. Herr, H. W.: Transurethral resection and intravesical therapy of superficial bladder tumors. Urol. Clin. N. Amer., 18: 525, 1991.
4. Simon, R.: Restricted randomization designs in clinical trials. Biometrics, 35: 503, 1979.
5. Kalbfleisch, J. D. and Prentice, R. L.: The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, Inc., 1980.
6. Cox, D. R.: Regression models and life tables. J. Roy. Stat. Soc., 34: 187, 1972.
7. Wei, L. J., Lin, D. Y. and Weissfeld, L.: Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J. Amer. Stat. Ass., 84: 1065, 1989.
8. Lin, D. Y.: MULCOX: a computer program for the Cox regression analysis of multiple failure time variables. Comput. Methods Prog. Biomed., 32: 125, 1990.
9. Sahai, H. and Khurshid, A.: Confidence intervals for the mean of a Poisson distribution. Biomed. J., 35: 857, 1993.
10. Breslow, N. E. and Day, N. E.: Statistical methods in cancer research. Volume II - the design and analysis of cohort studies. Int. Agency Res. Cancer Sci. Publ., pp. 1-406, 1987.
11. Heney, N. M., Koontz, W. W., Barton, B., Soloway, M., Trump, D. L., Hazra, T. and Weinstein, R. S.: Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J. Urol., 140: 1390, 1988.
12. Eure, G. R., Cundiff, M. R. and Schellhammer, P. F.: Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer. J. Urol., 147: 376, 1992.
13. Niijima, T., Koiso, K. and Akaza, H.: Randomized clinical trial for chemoprophylaxis of recurrence in cases of superficial bladder cancer. In: Proceedings of the 13th International Congress of Chemotherapy. Edited by K. H. Spitzy and K. Karrer. Vienna, Austria, pp. 240/6-240/8, August 28-September 2, 1983.
14. Kurth, K. H., Schröder, F. H., Tunn, U., Ay, R., Pavone-Macaluso, M., Debruyne, F., De Pauw, M., Dalesio, O., Ten Kate, F. and members of the European Organization for Research on Treatment of Cancer, Genitourinary Tract Cancer Cooperative Group: Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European Organization for Research on Treatment of Cancer randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection only. J. Urol., 132: 258, 1984.
15. Bouffioux, Ch., Denis, L., Oosterlinck, W., Viggiano, G., Vergison, B., Keuppens, F., De Pauw, M., Sylvester, R., Cheuvart, B. and members of the European Organization for Research on Treatment of Cancer Genitourinary Group: Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European Organization for Research on Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. J. Urol., 148: 297, 1992.
16. Martínez-Piñeiro, J. A., Leon, J. J., Martínez-Piñeiro, L., Jr., Fiter, L., Mosteiro, J. A., Navarro, J., Matres, M. J. G. and Cárcamo, P.: Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J. Urol., 143: 502, 1990.
17. Lamm, D. L.: Bacillus Calmette-Guerin immunotherapy for bladder cancer. J. Urol., 134: 40, 1985.
18. Cookson, M. S. and Sarosdy, M. F.: Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J. Urol., 148: 797, 1992.
19. Lamm, D. L. and Griffith, J. G.: Intravesical therapy: does it affect the natural history of superficial bladder cancer. Sem. Urol., 10: 39, 1992.
20. Lamm, D. L., Crissmann, J., Blumenstein, B. A., Crawford, E. D., Montie, J., Scardino, P., Grossman, H. B., Stanisic, T., Smith, J., Sullivan, J. and Sarosdy, M.: Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group study. In: BCG in Superficial Bladder Cancer. Edited by F. M. J. Debruyne, L. Denis and A. P. M. van der Meijden. New York: Alan R. Liss Inc., pp. 263-270, 1989.
21. Rintala, E., Jauhiainen, K., Alfthan, O., Hansson, E., Juusela, H., Kanerva, K., Korhonen, H., Permi, J., Sotarauta, M., Vaalasti, T., Viitanen, J. and Usenius, R.: Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. Eur. Urol., 20: 19, 1991.
22. Debruyne, F. M., van der Meijden, A. P. Witjes, J. A., Franssen, M. P. H., Steerenberg, P. A., DeJong, W. H., Read, J., van Leeuwen, M. J. W., Hammond, B. and Sylvester, R.: Bacillus Calmette-Guérin versus mitomycin C intravesical therapy in superficial bladder cancer. Results of randomized trial after 21 months of follow-up. Urology, suppl., 40: 11, 1992.
23. Witjes, J. A., van der Meijden, A. P., Witjes, W. P., Doesburg, W., Schaafsma, H. E. and Debruyne, F. M.: A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumors and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. Eur. J. Cancer, 29A: 1672, 1993.
24. Lamm, D. L., Steg, A., Boccon-Gibod, L., Morales, A., Hanna, M. G., Jr., Pagano, F., Alfthan, O., Brosman, S., Fisher, H. A., Jakse, G., Chisholm, G. D., van der Meijden, A. P. M. and Debruyne, F. M. J.: Complications of bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. Prog. Clin. Biol. Res., 310: 335, 1989.